K. Jedrychowicz‐Rosiak

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

J. Choe, J. Smolen, A. Baranauskaitė, 2015, Annals of the rheumatic diseases.

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

J. Choe, J. Smolen, W. Porawska, 2017, Annals of the rheumatic diseases.

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis

M. Weinblatt, A. Baranauskaitė, J. Ghil, 2018, Arthritis & rheumatology.

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

M. Weinblatt, J. Vencovský, J. Choe, 2017, Arthritis & rheumatology.

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results

J. Choe, J. Smolen, A. Baranauskaitė, 2017, Rheumatology.

The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.

W. White, G. Kitas, M. Weinblatt, 2014, Journal of the American Society of Hypertension : JASH.